The emergence of ORG NC 45, 1- [2 beta,3 alpha,5 alpha,16 beta,17 beta)-3, 17-bis(acetyloxy)-2-(1-piperidinyl)-androstan-16-yl]-1-methylpiperidinium bromide, from the pancuronium series.
A novel approach is described for obtaining a drug that will be a potent non-depolarizing neuromuscular blocking agent with the potential for a short duration of action and little cumulative effect. This approach led to the discovery of Org NC 45, from the pancuronium series.
D000818:Animals; D002415:Cats; D055598:Chemical Phenomena; D002621:Chemistry; D002626:Chemistry, Pharmaceutical; D006801:Humans; D009466:Neuromuscular Blocking Agents; D010197:Pancuronium / Q000031:analogs & derivatives* / Q000494:pharmacology; D051381:Rats; D013329:Structure-Activity Relationship; D014630:Vagus Nerve / Q000187:drug effects; D014673:Vecuronium Bromide
D009466:Neuromuscular Blocking Agents; D014673:Vecuronium Bromide; D010197:Pancuronium